{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigjlyskfst3mywkezxqe5jiplt57qzbjwhnmwrj5hq7vtqqvysm3y",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mhp6mih3g6p2"
  },
  "path": "/2026/03/23/everest-medicines-enters-into-asset-purchase-agreement-with-corxel-pharmaceuticals-to-develop-and-commercialize-cardamyst-etripamil-nasal-spray-in-greater-china/",
  "publishedAt": "2026-03-23T02:24:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "SHANGHAI, March 23, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited (“CORXEL”). Under the agreement, the Company has acquired the rights […]",
  "title": "Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China"
}